• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    India’s New Medical Devices Rules

    Discovering Packaging’s Hidden Value

    Deliberate Disposal: Single-Use & Disposables Technologies

    Illuminating Tubing’s Future

    Positive Identification: An Examination of Converting, Labeling, and Printing
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Using AI to Detect Arterial Stiffness

    FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach

    Medtronic Launches OptiSphere Embolization Spheres in the U.S.

    FDA Clears Cantel Medical's Automated Endoscope Reprocessor

    Business and Medical Leaders Join BioSig Technologies Advisory Board
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    India’s New Medical Devices Rules

    Discovering Packaging’s Hidden Value

    Deliberate Disposal: Single-Use & Disposables Technologies

    Illuminating Tubing’s Future

    Positive Identification: An Examination of Converting, Labeling, and Printing
    Top 30 Medical Device Companies
    Top Top 30
    Top 30 Global Medical Device Companies

    1. Medtronic plc

    2. Johnson & Johnson

    3. GE Healthcare

    4. Siemens Healthineers
    Market Data
    Datawatch Column
    Salary Survey
    White Papers
    Top Research
    Extolling the Virtues of Surgical Simulation

    Will Medtech M&A Mania Continue?

    Learn from My Mistakes: Why You Need a Quality System

    Brexit: D-Day or the Y2K for Global Supply Chains?

    Planning for Brexit
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    BMPmedical

    Vesta Inc.

    MTD Micro Molding

    Currier Plastics Inc.

    Teel Plastics
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    Slideshows
    Top Resources
    Single-Use Device Reprocessing Tailwinds and Headwinds

    Healthcare Artificial Intelligence Market to Register Commendable 40 Percent CAGR Over 2017-2024

    Finding Talent in Healthcare IoT

    Transforming from Supplier to Partner

    Building a Better Package
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Salary Survey
      • Market Data
      • Datawatch Column
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Four Takeaways from Recent Regulatory Audit Changes

    Related CONTENT
    • EtQ Announces New Life Science Features in its Traqpath Product
    • FDA Warns of Potential Fires and Explosions From Battery-Powered Medical Carts
    • Strategies for Effective Audits in the Medical Device Industry
    • FDA Clears Voxello's Speech Generation Device
    • Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use
    Alexa Sussman, Content Marketing Writer, EtQ05.01.17
    From medical device production to pharmaceutical manufacturing, the life sciences demand highly regulated operations. In a perfect world, these products would be without defect every time, but the reality is processes can stray from compliance and cause quality issues that affect people’s health.

    Therefore, audits are necessary to maintain compliance in a fast-paced business landscape with so much impact on the health of its consumers. When an organization knows an audit is approaching, they ensure their processes, documents, and products are all up to regulatory standards. Constantly maintaining a state of audit-readiness leads organizations to be efficient and in compliance at all times.

    Since audits are both a motivation for compliance and a diagnostic tool to identify organizational strengths and weaknesses, regulatory bodies must be smart with audit requirements so organizations continue to see them as an opportunity rather than a pain point. They constantly revise surrounding laws to make processes effective and efficient for both them and the participating manufacturers.

    Latest Changes in Regulatory Audit Law
    When regulatory audit laws change, the medical device and pharmaceutical industries feel the impact. Recently, there have been major updates to these laws to change the process on a global scale. The goal of these laws is for countries to recognize the audits and inspections of other countries, making the audit process a global, collaborative act.

    Early in March, Canada launched the Medical Device Single Audit Program (MDSAP). The new regulatory framework will tentatively replace the current Canadian Medical Devices Conformity Assessment System by January 2019. The replacement act allows medical device manufacturers to undergo a single audit that satisfies the requirements of all the participating countries: the United States, Australia, Brazil, Canada, and Japan.

    The U.S. Food and Drug Administration (FDA) and European Union (EU) announced similar updates around the same time. The FDA and the European Commission revealed the Mutual Recognition Agreement (MRA) on March 2. Under this regulatory framework, the United States and EU will be able to recognize each other’s audits at pharmaceutical manufacturing facilities. This act is an amendment to the 1998 Pharmaceutical Sectoral Annex, the original recognition between U.S. and EU regulatory bodies. These new standards will be officially recognized in November 2017, with plans for full implementation by 2019.

    Benefits of Single Audit Programs
    Single audit programs like these are great news for many medical device and pharmaceutical companies large and small. For example, many U.S. life science companies have some manufacturing sites outside of the United States. Of those outsourced outside the United States, most are in the EU. The MRA is extremely beneficial to those organizations.

    But it’s not just American companies that will benefit. One audit to satisfy multiple regulatory bodies’ requirements streamlines the entire audit process for all involved—both auditor and manufacturer. Following are some of the major benefits life science organizations and regulatory bodies will see under single audit programs, using the MRA as an example.

    1. Eased Pain Points with Harmonized Audit Programs
    Under this new regulatory framework, both the FDA and the EU will see more manageable workloads. When announcing the upcoming program earlier in March, the FDA said, “Strengthening the use of each other’s drug inspection expertise and resources will result in greater efficiencies for both regulatory systems and provide a more practical means to oversee the large number of drug manufacturing facilities.” Collaboration efforts between the two organizations will allow them to perform at a higher standard that takes the best from both parties.

    EU regulatory professionals agree. “The enhanced cooperation with U.S. regulatory authorities will improve the EU’s ability to identify and address problems at factories before they become a public health risk,” the European Commission announced in a press release.

    To create a successful multi-body program, regulatory bodies need to collaborate to create a harmonized audit plan that maintains consistency and an appropriate level of standards throughout. The FDA has outlined the steps it will take with the EU to create such an audit plan. Starting in 2014—with plans to finish before the end of 2017—the FDA has been observing and assessing scheduled audits for every EU country to determine the strength of their audit programs. Likewise, in September 2015, EU officials met at three different FDA district offices, and later began observing FDA audits in late 2016.

    Once their assessments are complete, U.S. and EU regulatory agencies will compare findings. By combining the most efficient and effective aspects of each party’s audit procedure, the agencies can create a single, harmonized set of standards. Taking the time to define best practices for audits and inspections now eases the workload in the future. It also instills confidence in pharmaceutical organizations that future audits will be standardized and complete, regardless of who conducts it.

    2. Lowered Costs
    Under the MRA, the FDA and EU must conduct as few as half the number of audits. This lowers the overall cost of quality for auditors because of the reduced amount of money spent on personnel, travel, and time to conduct on-site audits.

    However, this benefit of lowered costs extends beyond just auditors and regulatory bodies. “[The MRA] will also reduce administrative burdens and costs facing pharmaceutical manufacturers, including smaller producers,” the European Commission press release said. Reducing costs associated with interruption of business operations, audit preparation, and conducting the audit could result in many smaller manufacturers benefitting from increased profit margins.

    A mutually beneficial plan where both sides reduce operational costs is a benefit too important to overlook. Lowering costs for both auditors and manufacturers is a major highlight of a single audit program like the MRA.

    3. Reduction in Regulatory Pressure
    When it comes to audits, there is often pressure facing both those conducting the audits and those being audited. Manufacturers that would previously be audited by both the FDA and the EU often faced pressure to be simultaneously prepared for two completely different inspection processes, sometimes not knowing which would be next.

    Regulatory bodies faced pressure to inspect an ever-increasing number of sites in a short amount of time. They want to do their jobs completely and effectively because public health depends on it; however, focusing all their time on conducting and following up on audits diminishes any other priority tasks.

    Both the European Commission and the FDA have other initiatives and priorities beyond conducting audits, and they need just as much time and attention. Each organization can focus on things other than repeat audits thanks to more time available under a single audit program, rather than previous plans. For example, the FDA may be able to allocate more resources to tasks like streamlining the often-criticized drug approval process.

    The pressure will also be reduced on pharmaceutical manufacturing organizations to prepare for different audits from various regulatory bodies. Under the MRA, there will be less deviation from one regulatory body to the next. These organizations can then allot time to better plan for audits, setting long-term goals based off the single audit rather than scrambling to adjust plans already in motion. A standard audit provides organizations a set procedure for audit preparation, so the rest of their time can be spent on developing products and improving operational excellence.

    4. Eliminate Unnecessary Business Interruptions
    Previously, the EU and the FDA would both inspect some of the same facilities within the same year. This would be very disruptive for manufacturers as many operations would need to pause all operations more than once in a year to properly prepare for an audit or have it conducted. FDA inspections and regulatory audits are not quick and easy measures—preparation and conduction can take days. The absence of business interruptions allows for a continued workflow leading to streamlined processes.

    Regulatory bodies also won’t have their business interrupted as much to conduct audits that could potentially be unnecessary. Their resources can then be allocated more toward high-risk locations and reaching a larger amount of facilities in a shorter amount of time. In turn, this should lower the amount of public health issues stemming from pharmaceuticals while easing the workload of regulatory bodies.

    Preparing for (and Embracing) the Changes
    These upcoming changes will positively affect the life science industry. However, as with any change, organizations may have difficulties or hesitations when it comes to the transition. But once organizations embrace the new audit programs, they will see the benefits. Finally, a few tips for streamlining your audit process for success under the new program:
    • Incorporate software to store audit templates and download regulatory forms for quick access.
    • Use CAPAs when audits reveal less than stellar results to quickly and completely correct the issue.
    • Document and save all audit records to look back at what previous results were and plan for better future outcomes. 

    Alexa Sussman is a marketing content writer for EtQ. She is responsible for developing and writing content for EtQ, a leading enterprise quality and compliance management software vendor, as well as traqpath, EtQ’s compliance and event-tracking solution.
    Related Searches
    • body
    • standards
    • regulatory
    • compliance
    Suggested For You
    FDA Designates N8 Medical FDA Designates N8 Medical's CeraShield Endotracheal Tube as a Breakthrough Device
    FDA Clears First Whole Slide Imaging System for Digital Pathology FDA Clears First Whole Slide Imaging System for Digital Pathology
    Collaborating on Custom Materials Development Collaborating on Custom Materials Development
    Integrating Training and Document Control with Automated Solutions Integrating Training and Document Control with Automated Solutions
    Extractable/Leachable Chemistry Testing Strategies for Medical Devices Extractable/Leachable Chemistry Testing Strategies for Medical Devices
    Cheat Sheet for Corrective Actions in the Life Sciences Cheat Sheet for Corrective Actions in the Life Sciences
    Four Common Misperceptions of Accelerated FDA Approval Four Common Misperceptions of Accelerated FDA Approval
    FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device FDA Approves Increase in Number of Clinical Sites for E-QURE’s Pivotal Trial of BST Device
     FlowAid Receives FDA Clearance for the FA100 SCCD FlowAid Receives FDA Clearance for the FA100 SCCD
    Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use Capillus Laser Therapy Caps Receive FDA Clearance for Over-the-Counter Use
    FDA Clears Voxello FDA Clears Voxello's Speech Generation Device
    Strategies for Effective Audits in the Medical Device Industry Strategies for Effective Audits in the Medical Device Industry
    FDA Warns of Potential Fires and Explosions From Battery-Powered Medical Carts FDA Warns of Potential Fires and Explosions From Battery-Powered Medical Carts
    EtQ Announces New Life Science Features in its Traqpath Product EtQ Announces New Life Science Features in its Traqpath Product

    Related Columns

    • Software & IT | Surgical
      Extolling the Virtues of Surgical Simulation

      Extolling the Virtues of Surgical Simulation

      Gaining surgical competence for a new technique has a drastic learning curve. When surgeons are trained to perform a new procedure, however, the curriculum appears remarkably straightforward. Typically, the surgeon will attend a one- or two-day cours…
      Sam Brusco, Associate Editor 04.03.18

    • Will Medtech M&A Mania Continue?

      Will Medtech M&A Mania Continue?

      There are many opinions about the scope and scale of future medtech mergers after the M&A boom seen in 2016 and 2017. By June 2017, medical device M&A value rose 178 percent,1 propelled by the strategic imperative for medical device companies…
      Maria Shepherd, President and Founder, Medi-Vantage 04.03.18

    • Learn from My Mistakes: Why You Need a Quality System

      Learn from My Mistakes: Why You Need a Quality System

      I’ve made my share of stupid mistakes. When I was younger, most of them stemmed from just not thinking things through. I still cringe to admit I had some really big hair in the 1980s, one of many reasons I’ll be forever grateful my younge…
      Dawn A. Lissy, President & Founder, Empirical 04.03.18


    • Brexit: D-Day or the Y2K for Global Supply Chains?

      Brexit: D-Day or the Y2K for Global Supply Chains?

      On the same day Britons went to the polls to determine their country’s future with the European Union (EU), the Irish Business & Employers Confederation (IBEC) held a manufacturing conference in Dublin. IBEC represents the policy interests…
      Dan O’Mahony, Lifesciences Manager, Exertis Supply Chain Services Limited 04.03.18

    • Planning for Brexit

      Planning for Brexit

      Are you ISO 13485 certified by a United Kingdom Notified Body? Perhaps you’re a contract manufacturer serving OEM customers who are certified by a U.K. Notified Body. Either way, medical device companies must start preparing now to mollify the…
      James A. Dunning, Principal, QPC Services LLC 04.03.18

    • ISO 13485 2016: Upgrading to the New Edition (Part 1)

      ISO 13485 2016: Upgrading to the New Edition (Part 1)

      For the first time in 13 years, the International Organization for Standardization (ISO) has updated ISO 13485, the medical device industry’s framework for quality management systems (QMS). With an emphasis on risk management in the quality sys…
      Maria Fagan, President and Co-Founder, Regulatory and Quality Solutions LLC (R&Q) 04.03.18


    • Trade Wars—How Are You Impacted?

      Trade Wars—How Are You Impacted?

      Early last month, President Donald J. Trump ignited a firestorm on Twitter by expressing confidence that America would prevail in an international trade war on steel and aluminum. “When a country (USA) is losing many billions of dollars on trad…
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 04.03.18

    • Contract Manufacturing
      How Do I Serve Thee? Let Me Count the Ways

      How Do I Serve Thee? Let Me Count the Ways

      Perhaps it is obvious to most readers these days that using outsourced service providers (OSPs) can be a benefit to a client company. Historically, however, it has not been obvious. Back in the 80s and for much of the 90s, the idea of using outside r…
      David C. Robson, Principal, Robson Advisors 04.03.18

    • Funding New Ideas or Innovation

      Funding New Ideas or Innovation

      Everyone has the next big new idea, and in medtech, they don’t come cheap. But companies also don’t have to be valued in the billions of dollars to make an impact or get an idea moving forward.   The funding environment is hi…
      Marissa Fayer, President, Fayer Consulting LLC; CEO, HERHealthEQ; and Partner, LLEX Partners 04.03.18


    • The Not-So-Sweet Road to C-Suite Symmetry

      The Not-So-Sweet Road to C-Suite Symmetry

      Women have made great strides in the past half-century to end workplace gender disparity. They’ve gained legal safeguards (FMLA, Equal Pay Act, Pregnancy Discrimination Act), boosted their earnings potential, and gradually siphoned job market s…
      Michael Barbella, Managing Editor 03.15.18

    • Neurological
      The Development of New Medtech Markets Through Neurostimulation

      The Development of New Medtech Markets Through Neurostimulation

      The number of new disease states that can be addressed with implantable neurostimulation devices continues to grow.  The most common currently indicated use for these technologies is for the treatment of chronic pain—an enormous market tha…
      Maria Shepherd, President and Founder, Medi-Vantage 03.15.18

    • A Plan for Better Planning

      A Plan for Better Planning

      Planning is one of four business management functions (the others encompass organizing, leading, and controlling). Over the last several decades, the planning process has become a well-accepted tool in corporate America, especially for regulatory dep…
      James A. Dunning, Principal, QPC Services LLC 03.15.18

    • Software & IT
      How an Automated QMS Helps to Keep Up with  Regulatory Changes

      How an Automated QMS Helps to Keep Up with Regulatory Changes

      Medical device regulations are changing rapidly, and companies have limited time to comply. The deadline for ISO 13485:2016 is March 1, 2019, so organizations have just over a year to comply. Up until February 2018, organizations were able to be a…
      Alexa Sussman, Content Marketing Writer, EtQ 03.15.18

    • The Importance of Asking the Right Questions

      The Importance of Asking the Right Questions

      As M&A advisors that focus in healthcare (medical device, medical technology, dental, OEM, and biotechnology companies), we spend a lot of time talking to the “C-suite” among our clients, their acquirers, and their suppliers. We enjoy…
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 03.15.18

    • Materials
      Material World: Is Titanium the New PEEK?

      Material World: Is Titanium the New PEEK?

      The fanny pack is back. Give that a minute to sink in. According to Harper’s Bazaar, that’s one of 12 trends we all need to know about for 2018. I don’t spend much time thumbing through fashion tomes, but the occasional doctor&rs…
      Dawn A. Lissy, President & Founder, Empirical 03.14.18


    Breaking News
    • Using AI to Detect Arterial Stiffness
    • FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach
    • Medtronic Launches OptiSphere Embolization Spheres in the U.S.
    • FDA Clears Cantel Medical's Automated Endoscope Reprocessor
    • Business and Medical Leaders Join BioSig Technologies Advisory Board
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • India’s New Medical Devices Rules
    • Discovering Packaging’s Hidden Value
    • Deliberate Disposal: Single-Use & Disposables Technologies
    • Illuminating Tubing’s Future
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.